Latest news with #China-approved
Time of India
15-07-2025
- Business
- Time of India
Nvidia sparks buzz ahead of July 16 — will CEO Jensen Huang unveil the next big AI move?
Nvidia's big China comeback: H20 AI chip sales approved, stock jumps as CEO Jensen Huang teases major AI reveal on July 16- The story around Nvidia is heating up fast as we head into July 16. With the spotlight on CEO Jensen Huang, the tech world is waiting to see what's coming next in the AI race. Nvidia has already made headlines this week by scoring U.S. approval to resume sales of its H20 AI chips to China, and now there's growing talk that Huang might use his Beijing appearance to reveal a major move in AI. This event isn't just another industry update. It could shape how Nvidia plays in both the global AI chip market and China's booming tech sector. So what exactly is going on? Let's break it down. What's driving the buzz around Nvidia's July 16 event? The key reason behind the rising excitement is Nvidia's decision to hold a media briefing in Beijing on July 16, as confirmed by a company spokesperson. This will be Huang's second visit to China in 2024, signaling how serious Nvidia is about reconnecting with a region that once brought in around $17 billion in annual revenue. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Struggling With Belly Fat? Try This at Home Home Fitness Hack Shop Now Now that Nvidia is cleared to ship its advanced H20 chips to Chinese companies again, industry watchers believe Huang could use this opportunity to unveil a new AI strategy or even launch new chip models designed specifically for China, where U.S. tech restrictions have made things tricky in recent months. There's speculation that Nvidia may unveil a new China-approved chip , possibly a version of the Blackwell RTX Pro 6000 , tailored to meet U.S. export restrictions and support Chinese AI demand. Live Events Huang's visit is being watched closely in Washington. Two U.S. senators have warned him not to work with blacklisted Chinese companies , keeping Nvidia in a tight spot between U.S. rules and China sales. Despite pressure, Nvidia is betting big on its CUDA platform and local demand, as Chinese companies are lining up to buy the newly cleared H20 chips—especially before new U.S. restrictions hit again. Also Read: US stock market futures today: Nasdaq jumps on Nvidia's 5% surge after China chip news, S&P 500 hits record highs, Dow lags on trade tariff worries Why is Nvidia's China deal such a big deal? Until recently, Nvidia's business in China was under pressure due to U.S. government restrictions on exporting its high-end chips like the A100 and H100, which are widely used for training powerful AI models. To stay in the game, Nvidia developed new chips including the H20, L20, and L2, which are built to meet the U.S. export rules while still giving Chinese companies access to strong computing power. Now that the H20 chip has received U.S. approval, Nvidia is set to resume shipments. That's a huge win, considering the company reportedly lost about $4.5 billion in sales because of the previous restrictions. Major Chinese tech players like ByteDance, Alibaba, and Tencent are already lining up to buy. How did Nvidia's stock respond? Nvidia's stock surged in response to the news. On July 15, pre-market trading showed a 4.5% jump, with shares hitting around $171.40. This also helped lift the Nasdaq-100 index by 0.6%, showing how much influence Nvidia holds over the broader tech market. Investors are clearly optimistic. The approval to restart chip exports, combined with the anticipation of a big announcement from Huang, has created strong momentum for the stock. What are analysts predicting for Nvidia's future? Opinions are mixed—but the bull case is loud and clear. Many analysts believe Nvidia is still in the early innings of a long AI boom: According to a Nasdaq report, Nvidia could potentially reach a $5 trillion market cap by the end of 2025, driven by its dominance in GPU hardware and CUDA software that powers most AI models. Investopedia says that based on technical charts, Nvidia could climb toward $205 in the coming weeks if momentum holds, while $150 remains a strong support level. A Barron's piece even quotes a strategist who sees Nvidia overtaking Apple by market value, forecasting a price target as high as $250. On the flip side, DA Davidson, one of the more cautious voices, warned that AI demand might plateau in 2026. They see a downside to $135, or even $60 if market conditions shift drastically. What could Jensen Huang announce on July 16? While the company hasn't confirmed any specific product launches, industry experts think Huang might announce: New China-specific versions of Nvidia's upcoming Blackwell RTX Pro 6000 series Broader AI ecosystem plans to protect Nvidia's lead in software and training platforms Stronger local partnerships with Chinese tech firms to expand adoption under export limits Given the sensitive environment around U.S.–China tech policies, any new announcement will likely be designed to show Nvidia's ability to adapt without crossing any red lines. With the stock already testing highs again, investors are watching closely for what comes out of Beijing. If Huang delivers a bold vision, or if new product details come out, Nvidia could break above $180 in the short term, with some models pointing toward $205–$210 in the next few months. However, there are still risks. If global regulations tighten or if competitors like Huawei continue to gain ground in China, Nvidia could face new headwinds. FAQs: Q1: Why is Nvidia's July 16 event important for AI? It may reveal new AI chips or plans for China's market. Q2: Has Nvidia resumed H20 chip sales to China? Yes, U.S. cleared shipments and sales are restarting.
Yahoo
06-03-2025
- Business
- Yahoo
Ascentage Secures Third Breakthrough Therapy for Ph+ ALL Treatment
By Daniella Parra Ascentage Pharma (NASDAQ: AAPG; HKEX) said that its drug Olverembatinib is the first China-approved third-generation BCR-ABL inhibitor, and has been approved for certain chronic myeloid leukemia (CML) indications and included in China's National Reimbursement Drug List. Olverembatinib, is first-line treatment of newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in combination with low-intensity chemotherapy, Ascentage said. Ph+ ALL, which accounts for 20%-30% of adult ALL cases, has poor treatment tolerance and prognosis, with existing first- and second-generation tyrosine kinase inhibitors (TKIs) facing limitations such as high relapse rates, they said. 'We are much encouraged to have olverembatinib's clinical value once again recognized by the regulatory authority in China,' Dr. Yifan Zhai, Chief Medical Officer of Ascentage Pharma, said. 'This BTD underscores the therapeutic potential and utility of olverembatinib in Ph+ ALL, a hematologic malignancy with dismal prognosis. Moving forward, we will strive to accelerate this clinical development program for olverembatinib and bring it to more patients as quickly as possible.' Contact: Exec Edge Editor@ Sign in to access your portfolio
